Manager TitleAgeSince
Chief Executive Officer 61 2021-05-14
Director of Finance/CFO - 2016-12-31
Director TitleAgeSince
Director/Board Member 61 2021-05-14
Director/Board Member 67 2018-12-30
Chairman 62 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/1/21
Silver Point Capital LP
BuyCompany 187,061 0.1638%
12/30/20
Park West Asset Management LLC
OtherCompany 14,397,212 12.6041%
12/30/20 Sell

Director

20,000 0.0175%
Change 5-day change 1-year change 3-year change Capi.($)
-8.52%-5.36% - - 282M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -1.05%-0.59%+54.39%+120.28% 43.39B
Weighted average by Cap. +0.12%-0.84%+58.77%+129.91%
Logo PDL BioPharma, Inc.
PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.
Employees
-
  1. Stock Market
  2. Stocks
  3. PDLI Stock